A Dendritic Cell-Nanogel Conjugate for Tumor-Draining Lymph Node-Specific PD-L1 Blockade
Wenzhe Yi1,2, Xindi Qian1, Dan Yan1
1State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Abstract:
Targeted blockade of immune checkpoints within tumor-draining lymph nodes (TDLNs) represents a promising strategy to potentiate immune checkpoint blockade (ICB) therapy. However, the limited delivery of checkpoint inhibitors to TDLNs and inadequate T cell priming persist as major challenges. In this study, an innovative dendritic cell (DC)-based strategy is developed for the targeted delivery of ICB antibodies to TDLNs. The platform is fabricated by conjugating anti-PD-L1 antibody nanogels with DCs, which are further enhanced by pre-treating DCs with tumor antigens. Subcutaneous administration enabled DCs to execute their intrinsic TDLN-tropic migration, thus facilitating antibody delivery and release under reductive conditions. The antigen-loaded DCs mobilized T cell immunity, while the anti-PD-L1 antibodies block PD-L1 on dendritic cells and myeloid cells within TDLNs, thereby augmenting systemic antitumor immunity. This approach significantly suppresses breast cancer growth, leading to 83.3% of treated mice being tumor-free. This study presents a novel strategy for TDLN-targeted PD-L1 blockade by harnessing the intrinsic TDLN tropism of DCs, unveiling new translational opportunities of combining DC-based vaccination with ICB therapy.
Insights
This study developed a dendritic cell (DC) therapy to deliver immune checkpoint blockade (ICB) antibodies to tumor lymph nodes, significantly boosting anti-cancer immunity and achieving an 83.3% tumor-free rate in mice.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Targeted blockade of immune checkpoints in tumor-draining lymph nodes (TDLNs) can enhance immune checkpoint blockade (ICB) therapy.
- Challenges include limited delivery of inhibitors to TDLNs and insufficient T cell priming.
Purpose of the Study:
- To develop a novel dendritic cell (DC)-based strategy for targeted delivery of ICB antibodies to TDLNs.
- To enhance systemic antitumor immunity by combining DC vaccination with ICB therapy.
Main Methods:
- Conjugating anti-PD-L1 antibody nanogels with DCs pre-treated with tumor antigens.
- Utilizing the intrinsic TDLN-tropic migration of DCs for targeted delivery and release of antibodies in TDLNs.
- Assessing the suppression of breast cancer growth in a mouse model.
Main Results:
- The DC-based platform successfully delivered anti-PD-L1 antibodies to TDLNs.
- Antigen-loaded DCs enhanced T cell immunity, while PD-L1 blockade augmented systemic antitumor immunity.
- This approach led to significant suppression of breast cancer growth, with 83.3% of treated mice becoming tumor-free.
Conclusions:
- Harnessing DC tropism offers a novel strategy for TDLN-targeted PD-L1 blockade.
- Combining DC-based vaccination with ICB therapy presents new translational opportunities for cancer treatment.
More Related Videos
07:45Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
Published on: January 26, 2024
07:04Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
